Subscribe

The Future of Immuno-oncology in Advanced Lung Cancer

Conference Correspondent - ASCO 2016 - Lung Cancer
Benjamin P. Levy, MD
Benjamin P. Levy, MD, discusses the value in leveraging clinical trials to determine the potential of utilizing checkpoint inhibitors as single agent first line therapies and in combination with chemotherapy as a second line strategy.
Related Items
Utilizing Chemotherapy to Treat Lung Cancer
Benjamin P. Levy, MD
Conference Correspondent published on June 6, 2016 in ASCO 2016 - Lung Cancer
Treating Patients with Acquired TKI Resistance
Benjamin P. Levy, MD
Conference Correspondent published on June 4, 2016 in ASCO 2016 - Lung Cancer
Targeting the VEGF Axis in Advanced NSCLC
Benjamin P. Levy, MD
Conference Correspondent published on June 4, 2016 in ASCO 2016 - Lung Cancer
Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate-017/057 2-y update and exploratory cytokine profile analyses
Conference Correspondent published on June 3, 2016 in ASCO 2016 - Lung Cancer
Response to tyrosine kinase inhibitors in advanced non–small-cell lung cancer with concomitant c-MET overexpression and EGFR mutation
Conference Correspondent published on June 3, 2016 in ASCO 2016 - Lung Cancer
Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C
Conference Correspondent published on June 3, 2016 in ASCO 2016 - Lung Cancer
A randomized, open label, phase II study comparing pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant NSCLC patients who have failed first-line EGFR TKI: KCSG-LU12-13
Conference Correspondent published on June 3, 2016 in ASCO 2016 - Lung Cancer
A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study
Conference Correspondent published on June 3, 2016 in ASCO 2016 - Lung Cancer
Bayesian randomized trial comparing intensity-modulated radiation therapy versus passively scattered proton therapy for locally advanced non–small-cell lung cancer
Conference Correspondent published on June 3, 2016 in ASCO 2016 - Lung Cancer
E1505: Adjuvant chemotherapy ± bevacizumab for early stage NSCLC—outcomes based on chemotherapy subsets
Conference Correspondent published on June 3, 2016 in ASCO 2016 - Lung Cancer
Last modified: June 4, 2016
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology